COVID-19, thromboembolic risk and thromboprophylaxis: learning lessons from the bedside, awaiting evidence.

PreviewOver the past four months, COVID-19, the disease associated with the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), emerged in Wuhan and the Hubei province of China1 and spread worldwide, overwhelming healthcare systems and causing significant mortality. Among Western countries, Italy, and in particular the northern regions, were the first to have to face the COVID-19 epidemic emergency, at a time when knowledge about the disease was limited and little data about management and treatment were available in the literature. [ … ]